Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04362072
Title Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Lorlatinib

Age Groups: adult | senior
Covered Countries USA | ITA | ESP

Additional content available in CKB BOOST